Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
November 13th, 2008 by 
admin Authors: Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT
The identification of binary myeloma (MM) has been attendant to an accumulated venture of venous thromboembolic events (VTE). Described venture factors that are not inner to MM allow older age, chemotherapy, immobility, broad levels of tube endothelial ontogeny factor, cancer procoagulant and paraproteinemia. Disease-specific venture factors unequalled to MM are creation of procoagulant autoantibodies, a broad frequency of acquired reactive accelerator C resistance, accumulated levels of bourgeois octad and von doc factor, and accumulated creation of inflammatory cytokines, mainly IL-6, cytokine and C-reactive protein. Treatment regimens that allow thalidomide or attendant compounds much as lenalidomide compounded with glucocorticoids and/or cyto…
Posted in Cancer | 